AVIDITY PARTNERS MANAGEMENT LP
Q1 2024 Form 13-F
DALLAS, TEXAS
CIK 0001791827
· CRD 304628
· SEC-registered investment adviser
$3.1B Reported Value Total
AVIDITY PARTNERS MANAGEMENT LP reports 10 total accounts under management (AUM). There are 10 discretionary accounts valued at $5,268,891,937, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
4 funds
· $1.1B gross asset value
Hedge Fund: $1.1B
Source: Form ADV filed 2026-10-30
Reported value
$3.1B
Quarter over quarter
+12.3%
Holdings
87
Top-10 concentration
35.6%
Key People
Form ADV owners & control persons
Michael David Gregory
MANAGING PARTNER, DIRECTOR OF RESEARCH, PRESIDENT OF BUSINESS OPERATIONS
Christopher David Connors
CHIEF FINANCIAL OFFICER
Jose Antonio Santiago
CHIEF COMPLIANCE OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q1 2024 13F record
Q1 2024 13F filing summary
| Period of report | March 31, 2024 |
|---|---|
| Filed | May 15, 2024 |
| Form | 13F-HR |
| Reported value | $3.1B |
| Positions | 87 |
| Change in reported value | +13.0% |
| New positions | 33 |
| Exited positions | 18 |
| Position turnover | 48.6% |
| Top-10 concentration | 35.6% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 16, 2026
|
17 | $488.2M |
|
Q2 2026 13F
Filed Aug 14, 2026
|
45 | $624.4M |
|
Q1 2026 13F
Filed May 13, 2026
|
52 | $505.3M |
|
Q4 2025 13F
Filed Feb 13, 2026
|
39 | $346.7M |
|
Q3 2025 13F
Filed Nov 14, 2025
|
43 | $439.4M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
55 | $502.0M |
|
Q1 2025 13F
Filed May 15, 2025
|
63 | $524.7M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
61 | $1.0B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
81 | $2.0B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
85 | $2.4B |
|
Q1 2024 13F
Filed May 15, 2024
|
87 | $3.1B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
72 | $2.7B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
83 | $2.5B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
93 | $2.9B |
|
Q1 2023 13F
Filed May 15, 2023
|
83 | $3.0B |
|
Q4 2022 13F
Filed Feb 14, 2023
|
84 | $4.6B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
95 | $4.9B |
|
Q2 2022 13F
Filed Aug 15, 2022
|
82 | $4.4B |
|
Q1 2022 13F
Filed May 16, 2022
|
91 | $4.8B |
|
Q4 2021 13F
Filed Feb 14, 2022
|
97 | $4.7B |
8 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q1 2024
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | ITCI C INTRA-CELLULAR THERAPIES INC | $239.5M | 7.72% |
| 2 | FUSN FUSION PHARMACEUTICALS INC | $138.6M | 4.47% |
| 3 | BSX BOSTON SCIENTIFIC CORP | $134.0M | 4.32% |
| 4 | ARVN ARVINAS INC | $123.2M | 3.97% |
| 5 | ISRG INTUITIVE SURGICAL INC | $90.2M | 2.91% |
| 6 | DNTH DIANTHUS THERAPEUTICS INC | $81.5M | 2.63% |
| 7 | ACHC ACADIA HEALTHCARE COMPANY IN | $79.6M | 2.57% |
| 8 | NBIX NEUROCRINE BIOSCIENCES INC | $74.0M | 2.39% |
| 9 | NTRA NATERA INC | $73.5M | 2.37% |
| 10 | JAZZ JAZZ PHARMACEUTICALS PLC | $70.3M | 2.27% |
| 11 | AVTR AVANTOR INC | $68.9M | 2.22% |
| 12 | CI THE CIGNA GROUP | $67.0M | 2.16% |
| 13 | MRK MERCK & CO INC | $66.2M | 2.14% |
| 14 | REGN REGENERON PHARMACEUTICALS | $65.4M | 2.11% |
| 15 | CGON CG ONCOLOGY INC | $63.9M | 2.06% |
| 16 | ILMN ILLUMINA INC | $63.7M | 2.05% |
| 17 | THC TENET HEALTHCARE CORP | $63.2M | 2.04% |
| 18 | ALGN ALIGN TECHNOLOGY INC | $62.0M | 2.0% |
| 19 | SNDX SYNDAX PHARMACEUTICALS INC | $57.4M | 1.85% |
| 20 | LLY ELI LILLY & CO | $54.5M | 1.76% |
Values as reported on the Q1 2024 Form 13F. Every position is in the holdings table below.